ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
FDA rejects approval of second low T product in the past month
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 11930" data-attributes="member: 3"><p>As of September 17, 2014 (last FDA meeting to review requirements for testosterone studies and products), approval of testosterone replacement products has become a lot more difficult in the United States. This was fueled by two flawed studies that linked testosterone to cardiovascular risks and also by the abuse in testosterone product marketing. These are the two last companies that have been affected since that day.</p><p></p><p></p><p>Published on FierceBiotech (<a href="http://www.fiercebiotech.com" target="_blank">http://www.fiercebiotech.com</a>)</p><p></p><p><strong>Repros plummets as the FDA deals a blow to its low-T hopes</strong></p><p></p><p>October 17, 2014 | By Damian Garde</p><p>After years of clinical and regulatory setbacks, Repros Therapeutics ($RPRX) was finally on the path to submitting its testosterone treatment to the FDA, scheduling a prefiling meeting for November with hopes of handing the drug in by year's end. But the agency has had some second thoughts, changing the agenda for that meeting and indefinitely delaying Repros' plans.</p><p></p><p>Last month, Repros heralded that it had nailed down a Type B pre-NDA meeting, in which FDA reviewers would guide on how to go about submitting Androxal, a small-molecule treatment for low testosterone. Now, however, the agency no longer considers Repros' clinical data to be sufficient, and it has changed the calendar entry to a Type C guidance meeting. What that means for Androxal's long-term regulatory fate is unclear, but it almost certainly nixes Repros' goal of an end-of-the-year filing.</p><p></p><p>The biotech's shares tanked more than 40% on the news, the latest setback for a company that has struggled for years to get its low-T drug on the market.</p><p></p><p>Repros said it doesn't know what led the FDA to change its mind on Androxal, but the agency's issue with the company's Phase III data are already well-established. Last year, Repros had to put off a planned mid-2014 filing for the drug when the agency called into question the company's chosen patient populations and endpoints in two late-stage trials. The parties eventually came to terms, with Repros amending its analysis, and the biotech believed it was finally on the path to Androxal's approval.</p><p></p><p>Things were looking up for Repros before its latest regulatory setback, as the company announced in August that Androxal beat out AbbVie's ($ABBV) top-selling AndroGel in boosting testosterone, one of two planned head-to-head studies. Furthermore, the company believed the FDA's recent scrutiny of testosterone-replacement therapies left Androxal, which isn't a form of testosterone, unscathed.</p><p></p><p>Repros hasn't given up hope for the oft-delayed treatment, pointing out that data packet under FDA consideration does not include results from a one-year safety or a drug-drug interaction trial, information the company believes may be significant to the agency's review.</p><p></p><p>This was the first company that was told they need more data after the Sept 17, 2014 meeting where the FDA said they will be more strict with testosterone companies seeking product approval:</p><p></p><p>September 19, 2014 </p><p></p><p>By Riley McDermid, BioSpace.com Breaking News Sr. Editor </p><p></p><p><strong>The U.S. Food and Drug Administration has shot down private company Clarus Therapeutics' oral testosterone drug Rextoro (oral testosterone undecanoate), </strong>saying Thursday that the company had not done enough to allay fears that testosterone therapy can lead to elevated risks of heart attack and other cardiovascular events. </p><p></p><p>The FDA's urologic and drug safety committees voted 18-3 with one abstention to deny Clarus's application for approval for the drug, saying the company had provided incomplete data from the drug's two Phase III trials. The FDA's final decision on Rextoro's fate is due by Nov. 3. - See more at: <a href="http://www.biospace.com/news_story.aspx?StoryID=347110&full=1#sthash.4TXkVg6Y.dpuf" target="_blank">http://www.biospace.com/news_story.aspx?StoryID=347110&full=1#sthash.4TXkVg6Y.dpuf</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 11930, member: 3"] As of September 17, 2014 (last FDA meeting to review requirements for testosterone studies and products), approval of testosterone replacement products has become a lot more difficult in the United States. This was fueled by two flawed studies that linked testosterone to cardiovascular risks and also by the abuse in testosterone product marketing. These are the two last companies that have been affected since that day. Published on FierceBiotech ([URL]http://www.fiercebiotech.com[/URL]) [B]Repros plummets as the FDA deals a blow to its low-T hopes[/B] October 17, 2014 | By Damian Garde After years of clinical and regulatory setbacks, Repros Therapeutics ($RPRX) was finally on the path to submitting its testosterone treatment to the FDA, scheduling a prefiling meeting for November with hopes of handing the drug in by year's end. But the agency has had some second thoughts, changing the agenda for that meeting and indefinitely delaying Repros' plans. Last month, Repros heralded that it had nailed down a Type B pre-NDA meeting, in which FDA reviewers would guide on how to go about submitting Androxal, a small-molecule treatment for low testosterone. Now, however, the agency no longer considers Repros' clinical data to be sufficient, and it has changed the calendar entry to a Type C guidance meeting. What that means for Androxal's long-term regulatory fate is unclear, but it almost certainly nixes Repros' goal of an end-of-the-year filing. The biotech's shares tanked more than 40% on the news, the latest setback for a company that has struggled for years to get its low-T drug on the market. Repros said it doesn't know what led the FDA to change its mind on Androxal, but the agency's issue with the company's Phase III data are already well-established. Last year, Repros had to put off a planned mid-2014 filing for the drug when the agency called into question the company's chosen patient populations and endpoints in two late-stage trials. The parties eventually came to terms, with Repros amending its analysis, and the biotech believed it was finally on the path to Androxal's approval. Things were looking up for Repros before its latest regulatory setback, as the company announced in August that Androxal beat out AbbVie's ($ABBV) top-selling AndroGel in boosting testosterone, one of two planned head-to-head studies. Furthermore, the company believed the FDA's recent scrutiny of testosterone-replacement therapies left Androxal, which isn't a form of testosterone, unscathed. Repros hasn't given up hope for the oft-delayed treatment, pointing out that data packet under FDA consideration does not include results from a one-year safety or a drug-drug interaction trial, information the company believes may be significant to the agency's review. This was the first company that was told they need more data after the Sept 17, 2014 meeting where the FDA said they will be more strict with testosterone companies seeking product approval: September 19, 2014 By Riley McDermid, BioSpace.com Breaking News Sr. Editor [B]The U.S. Food and Drug Administration has shot down private company Clarus Therapeutics' oral testosterone drug Rextoro (oral testosterone undecanoate), [/B]saying Thursday that the company had not done enough to allay fears that testosterone therapy can lead to elevated risks of heart attack and other cardiovascular events. The FDA's urologic and drug safety committees voted 18-3 with one abstention to deny Clarus's application for approval for the drug, saying the company had provided incomplete data from the drug's two Phase III trials. The FDA's final decision on Rextoro's fate is due by Nov. 3. - See more at: [URL]http://www.biospace.com/news_story.aspx?StoryID=347110&full=1#sthash.4TXkVg6Y.dpuf[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
FDA rejects approval of second low T product in the past month
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top